Weekly paclitaxel plus capecitabine versus docetaxel every 3 weeks plus capecitabine in metastatic breast cancer

Journal of Oncology

Volumn , Issue , 2012, Pages

  Wist, E A ^a   Mjaaland, I ^b   Lokkevik E ^a   Sommer, H H ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOCETAXEL; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; METASTATIC BREAST CANCER; MUCOSA INFLAMMATION; NAIL DISEASE; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; TIME TO TREATMENT FAILURE;

EID: 84856427510     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/862921     Document Type: Article

References (21)

1. Sjstrm J., Blomqvist C., Mouridsen H., Pluzanska A., Ottosson-Lnn S., Bengtsson N. O., stenstad B., Mjaaland I., Palm-Sjvall M., Wist E., Valvere V., Anderson H., Bergh J., Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group European Journal of Cancer 1999 35 8 1194 1201 (Pubitemid 29359178)
2. Nabholtz J.-M., Senn H. J., Bezwoda W. R., Melnychuk D., Deschnes L., Douma J., Vandenberg T. A., Rapoport B., Rosso R., Trillet-Lenoir V., Drbal J., Molino A., Nortier J. W.R., Richel D. J., Nagykalnai T., Siedlecki P., Wilking N., Genot J. Y., Hupperets P. S.G.J., Pannuti F., Skarlos D., Tomiak E. M., Murawsky M., Alakl M., Riva A., Aapro M., Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy Journal of Clinical Oncology 1999 17 5 1413 1424 (Pubitemid 29220847)
3. Fountzilas G., Athanassiades A., Giannakakis T., Bafaloukos D., Karakousis K., Dombros N., Kosmidis P., Skarlos D., A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines European Journal of Cancer 1996 32 1 47 51
4. Smith R. E., Brown A. M., Mamounas E. P., Anderson S. J., Lembersky B. C., Atkins J. H., Shibata H. R., Baez L., DeFusco P. A., Davila E., Tipping S. J., Bearden J. D., Thirlwell M. P., Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26 Journal of Clinical Oncology 1999 17 11 3403 3411 (Pubitemid 29517907)
5. Nabholtz J.-M., Gelmon K., Bontenbal M., Spielmann M., Catimel G., Conte P., Klaassen U., Namer M., Bonneterre J., Fumoleau P., Winograd B., Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer Journal of Clinical Oncology 1996 14 6 1858 1867 (Pubitemid 26185461)
6. Seidman A. D., Tiersten A., Hudis C., Gollub M., Barrett S., Yao T. J., Lepore J., Gilewski T., Currie V., Crown J., Hakes T., Baselga J., Sklarin N., Moynihan M. E., Tong W., Egorin M., Kearns C., Spriggs D., Norton L., Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer Journal of Clinical Oncology 1995 13 10 2575 2581
7. Davidson N. G., Chick J. B., Perren T. J., Campbell N., Thompson J. M., Chan Y. T. S., A phase II study of single agent paclitaxel in patients at first relapse following initial chemotherapy for breast cancer Clinical Oncology 1996 8 6 358 362
8. Perez E. A., Vogel C. L., Irwin D. H., Kirshner J. J., Patel R., Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer Journal of Clinical Oncology 2001 19 22 4216 4223 (Pubitemid 33081639)
9. Seidman A. D., Hudis C. A., Albanel J., Tong W., Tepler I., Currie V., Moynahan M. E., Theodoulou M., Gollub M., Baselga J., Norton L., Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer Journal of Clinical Oncology 1998 16 10 3353 3361 (Pubitemid 28481632)
10. Sola C., Lluch A., Garcia-Conde J., Phase II study of weekly paclitaxel treatment in recurrent breast cancer after high dose chemotherapy Proceedings of the American Society of Clinical Oncology 1999 18: 135a, abstract 515
11. Wist E. A., Sommer H. H., stenstad B., Risberg T., Fjstad K., Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer Acta Oncologica 2004 43 1 11 14 (Pubitemid 38283167)
12. O'Shaughnessy J., Miles D., Vukelia S., Moiseyenko V., Ayoub J. P., Cervantes G., Fumoleau P., Jones S., Lui W. Y., Mauriac L., Twelves C., Van Hazel G., Verma S., Leonard R., Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results Journal of Clinical Oncology 2002 20 12 2812 2823 (Pubitemid 34651510)
13. Blum J. L., Dees E. C., Chacko A., Doane L., Ethirajan S., Hopkins J., McMahon R., Merten S., Negron A., Neubauer M., Ilegbodu D., Boehm K. A., Asmar L., O'Shaughnessy J. A., Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer Journal of Clinical Oncology 2006 24 27 4384 4390 (Pubitemid 46630975)
14. Therasse P., Arbuck S. G., Eisenhauer E. A., Wanders J., Kaplan R. S., Rubinstein L., Verweij J., Van Glabbeke M., Van Oosterom A. T., Christian M. C., Gwyther S. G., New guidelines to evaluate the response to treatment in solid tumors Journal of the National Cancer Institute 2000 92 3 205 216 (Pubitemid 30099779)
15. WHO Handbook for Reporting Results of Cancer Treatment 1979 WHO Offset Publication no. 48
16. Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A., EORTC QLQ-C30 Scoring Manual 2001 3rd Brussels, Belgium European Organization for Research and Treatment of Cancer
17. Susnjar S., Bosnjak S., Radulovic S., Sevanovic J., Gajic-Dobrosavljevic M., Keacic M., Dose-finding study of capecitabine in combination with weekly paclitaxel fo patients with anthracycline-pretreated metastatic breast cancer Journal of B.U.ON. 2007 12 2 189 196 (Pubitemid 47038996)
18. Uhlmann C., Ballabeni P., Rijken N., Brauchli P., Mingrone W., Rauch D., Pestalozzi B. C., Rochlitz C., Aebi S., Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial Oncology 2004 67 2 117 122 (Pubitemid 39482679)
19. Di Costanzo F., Gasperoni S., Papaldo P., Bilancia D., Manzione L., Landucci E., Mazzoni F., Cognetti F., Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL Annals of Oncology 2006 17 1 79 84 (Pubitemid 43033844)
20. Gennari A., Stockler M., Puntoni M., Sormani M., Nanni O., Amadori D., Wilcken N., D'Amico M., DeCensi A., Bruzzi P., Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials Journal of Clinical Oncology 2011 29 16 2144 2149
21. Scapira L., Optimal Duration of Chemotherapy in Metastatic Breast Cancer. Medscape hematology-oncology: viewpoints. 2011